The association of alanine aminotransferase within the normal and mildly elevated range with lipoproteins and apolipoproteins: The Insulin Resistance Atherosclerosis Study

Diabetologia

Volumn 56, Issue 4, 2013, Pages 746-757

  Lorenzo, C ^a   Hanley, A J ^b,c   Rewers, M J ^d   Haffner, S M ^e,f  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF COLORADO DENVER   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f NONE

Author keywords

Apolipoproteins; Insulin resistance; Lipoproteins; NMR spectrometry; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN; APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DEMOGRAPHY; DYSLIPIDEMIA; FEMALE; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NUCLEAR MAGNETIC RESONANCE; OBESITY; PARTICLE SIZE; PRIORITY JOURNAL;

ADIPOSITY; ADULT; AGED; ALANINE TRANSAMINASE; APOLIPOPROTEINS; ATHEROSCLEROSIS; CHRONIC DISEASE; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 84876490780     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2826-4     Document Type: Article

References (49)

1. Xu J, Kochanek KD, Murphy SL, Tejada-Vera B (2010) Deaths: final data for 2007. Natl Vital Stat Rep 58:19
2. Younossi ZM, Stepanova M, Afendy M et al (2011) Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 9:524-530
3. Mulhall BP, Ong JP, Younossi ZM (2002) Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 17:1136-1143
4. Schindhelm RK, Dekker JM, Nijpels G et al (2007) Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191:391-396
5. Ford I, Mooijaart SP, Lloyd S et al (2011) The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. Int J Epidemiol 40:1530-1538
6. Lazo M, Hernaez R, Bonekamp S et al (2011) Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 343:d6891
7. Hanley AJ, Williams K, Festa A et al (2004) Elevations in markers of liver injury and risk of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 53:2623-2632
8. Lee DH, Ha MH, Kim JH et al (2003) Gamma-glutamyltransferase and diabetes - a 4 year follow-up study. Diabetologia 46:359-364
9. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM (2005) Liver markers and development of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Diabetes 54:3140-3147
10. Marchesini G, Brizi M, Bianchi G et al (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844-1850
11. Hanley AJ, Wagenknecht LE, Festa A, D'Agostino RB Jr, Haffner SM (2007) Alanine aminotransferase and directly measured insulin sensitivity in a multiethnic cohort: the Insulin Resistance Atherosclerosis Study. Diabetes Care 30:1819-1827
12. Adiels M, Taskinen MR, Packard C et al (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49:755-765
13. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC (2003) Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 285:E906-E916
14. Kotronen A, Yki-Järvinen H, Sevastianova K et al (2011) Comparison of the relative contributions of intra-abdominal and liver fat to components of the metabolic syndrome. Obesity (Silver Spring) 19:23-28
15. Burgert TS, Taksali SE, Dziura J et al (2006) Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab 91:4287-4294
16. McKimmie RL, Daniel KR, Carr JJ et al (2008) Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 103:3029-3035
17. Bethel MA, Deedwania P, Levitt NS et al (2009) Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population. Diabet Med 26:1204-1211
18. Kazumi T, Kawaguchi A, Hirano T, Yoshino G (2006) Serum alanine aminotransferase is associated with serum adiponectin, C-reactive protein and apolipoprotein B in young healthy men. Horm Metab Res 38:119-124
19. Kelishadi R, Cook SR, Amra B, Adibi A (2009) Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. Atherosclerosis 204:538-543
20. Otvos JD (2002) Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48:171-180
21. Festa A, Williams K, Hanley AJ et al (2005) Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 111:3465-3472
22. Lyons TJ, Jenkins AJ, Zheng D et al (2006) Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabet Med 23:955-966
23. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM (2009) Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 119:931-939
24. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM (2010) Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 59:1153-1160
25. Westerbacka J, Cornér A, Tiikkainen M et al (2004) Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 47:1360-1369
26. Wagenknecht LE, Mayer EJ, Rewers M et al (1995) The insulin resistance atherosclerosis study: design, objectives and recruitment results. Ann Epidemiol 5:464-472
27. Pacini G, Bergman RN (1986) MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 23:113-122
28. Laws A, Hoen HM, Selby JV, Saad MF, Haffner SM, Howard BV (1997) Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Arterioscler Thromb Vasc Biol 17:64-71
29. D'Agostino RB Jr, Hamman RF, Karter AJ, Mykkanen L, Wagenknecht LE, Haffner SM (2004) Cardiovascular disease risk factors predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes Care 27:2234-2240
30. Kudoh A, Sakai T, Ishihara H, Matsuki A (1997) Increase in serum creatine phosphokinase concentrations after suxamethonium during sevoflurane or isoflurane anaesthesia in children. Br J Anaesth 78:372-374
31. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42-47
32. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome - a new worldwide definition. Lancet 366:1059-1062
33. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
34. Kotronen A, Peltonen M, Hakkarainen A et al (2009) Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137:865-872
35. Angulo P, Hui JM, Marchesini G et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846-854
36. Sterling RK, Lissen E, Clumeck N et al (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43:1317-1325
37. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM et al (2002) Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:3023-3028
38. Simonen P, Kotronen A, Hallikainen M et al (2011) Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol 54:153-159
39. Fabbrini E, Magkos F, Mohammed BS et al (2009) Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 106:15430-15435
40. Nannipieri M, Gonzales C, Baldi S et al (2005) Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City Diabetes Study. Diabetes Care 28:1757-1762
41. Oh SY, Cho YK, Kang MS et al (2006) The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 55:1604-1609
42. Lazo M, Solga SF, Horska A et al (2010) Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 33:2156-2163
43. Després JP, Ross R, Boka G, Alméras N, Lemieux I (2009) Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 29:416-423
44. Walldius G, Jungner I (2005) Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur Heart J 26:210-212
45. Brewer HB (2004) Increasing HDL cholesterol levels. N Engl J Med 350:1491-1494
46. D'Adamo E, Northrup V, Weiss R et al (2010) Ethnic differences in lipoprotein subclasses in obese adolescents: importance of liver and intraabdominal fat accretion. Am J Clin Nutr 92:500-508
47. Guerrero R, Vega GL, Grundy SM, Browning JD (2009) Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 49:791-801
48. Vozarova B, Stefan N, Lindsay RS et al (2002) High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51:1889-1895
49. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP (2010) Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59:1265-1269